Your browser is no longer supported. Please, upgrade your browser.
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E16.44 EPS (ttm)4.57 Insider Own0.40% Shs Outstand94.70M Perf Week-5.20%
Market Cap6.91B Forward P/E25.25 EPS next Y2.97 Insider Trans-15.22% Shs Float93.04M Perf Month-11.30%
Income444.80M PEG1.36 EPS next Q0.57 Inst Own97.40% Short Float3.03% Perf Quarter-27.79%
Sales1.07B P/S6.46 EPS this Y977.20% Inst Trans0.24% Short Ratio3.18 Perf Half Y-23.77%
Book/sh14.21 P/B5.29 EPS next Y88.71% ROA23.60% Target Price118.86 Perf Year-35.76%
Cash/sh8.33 P/C9.02 EPS next 5Y12.10% ROE35.90% 52W Range71.88 - 120.27 Perf YTD-11.82%
Dividend- P/FCF21.43 EPS past 5Y42.90% ROI30.80% 52W High-37.56% Beta0.80
Dividend %- Quick Ratio4.30 Sales past 5Y121.20% Gross Margin98.80% 52W Low4.49% ATR3.45
Employees845 Current Ratio4.50 Sales Q/Q14.50% Oper. Margin18.00% RSI (14)38.54 Volatility4.16% 4.00%
OptionableYes Debt/Eq0.00 EPS Q/Q137.30% Profit Margin41.60% Rel Volume1.36 Prev Close72.80
ShortableYes LT Debt/Eq0.25 EarningsFeb 10 AMC Payout0.00% Avg Volume884.72K Price75.10
Recom2.10 SMA20-7.03% SMA50-10.00% SMA200-19.29% Volume1,203,029 Change3.16%
Jan-18-22Downgrade RBC Capital Mkts Outperform → Sector Perform $122 → $90
Nov-19-21Initiated BMO Capital Markets Underperform $76
Nov-17-21Upgrade JP Morgan Neutral → Overweight $124
Oct-14-21Downgrade Morgan Stanley Overweight → Equal-Weight $110 → $112
Sep-23-21Resumed Needham Hold
Aug-06-21Downgrade Canaccord Genuity Buy → Hold
May-18-21Resumed Goldman Neutral $108
May-06-21Upgrade Barclays Equal Weight → Overweight $110
Feb-02-21Initiated Raymond James Outperform $163
Sep-30-20Initiated The Benchmark Company Hold
Aug-04-20Downgrade JP Morgan Overweight → Neutral $136
Jun-29-20Downgrade Goldman Buy → Neutral $135
Jun-09-20Initiated Wedbush Outperform $147
Mar-06-20Initiated Citigroup Buy $124
Feb-27-20Initiated Barclays Equal Weight $105
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Feb-05-20Reiterated H.C. Wainwright Buy $102 → $125
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jan-12-22 05:38PM  
10:43AM  
Jan-06-22 04:01PM  
Jan-03-22 04:01PM  
Dec-28-21 07:38AM  
Dec-17-21 10:38PM  
Dec-14-21 11:38PM  
Dec-10-21 01:36PM  
Dec-09-21 08:16AM  
Dec-08-21 07:38PM  
Dec-07-21 04:35PM  
Dec-06-21 11:32AM  
Nov-30-21 04:05PM  
Nov-22-21 08:00AM  
Nov-09-21 04:01PM  
Nov-02-21 03:14PM  
Nov-01-21 10:00PM  
05:15PM  
04:01PM  
08:00AM  
Oct-26-21 10:36AM  
Oct-25-21 03:01PM  
Oct-18-21 12:31PM  
Oct-16-21 05:00PM  
Oct-13-21 11:30AM  
Oct-11-21 04:01PM  
Oct-08-21 07:29AM  
Sep-20-21 08:52AM  
Sep-10-21 09:23AM  
Sep-08-21 08:30AM  
Sep-02-21 04:13PM  
Aug-05-21 04:01PM  
06:14AM  
Aug-03-21 10:31PM  
05:25PM  
04:01PM  
Jul-27-21 03:03PM  
Jul-22-21 12:10PM  
Jul-19-21 04:01PM  
Jul-08-21 04:01PM  
Jul-06-21 11:49AM  
Jun-21-21 05:53AM  
Jun-01-21 04:01PM  
May-11-21 04:01PM  
May-06-21 06:14AM  
12:01AM  
May-05-21 05:15PM  
04:01PM  
02:45PM  
May-04-21 04:01PM  
May-03-21 08:30AM  
Apr-28-21 12:34PM  
Apr-26-21 04:01PM  
Apr-19-21 03:51PM  
Apr-16-21 09:00AM  
Apr-14-21 04:01PM  
Apr-08-21 04:01PM  
Mar-26-21 09:33AM  
Mar-25-21 04:01PM  
03:34PM  
Mar-24-21 06:35PM  
Mar-22-21 07:21AM  
Mar-20-21 11:00AM  
Mar-18-21 06:02PM  
Mar-09-21 04:01PM  
Mar-02-21 08:53AM  
07:30AM  
Feb-23-21 04:01PM  
Feb-04-21 11:31PM  
05:55PM  
04:49PM  
04:01PM  
02:45PM  
04:00AM  
Feb-02-21 04:01PM  
Jan-28-21 12:32PM  
Jan-20-21 04:01PM  
Jan-08-21 10:15AM  
07:30AM  
Jan-04-21 04:01PM  
Dec-22-20 04:17PM  
Dec-21-20 11:36AM  
04:22AM  
Dec-11-20 08:58AM  
Dec-09-20 07:51AM  
Nov-19-20 09:00AM  
08:00AM  
Nov-13-20 07:29AM  
Nov-10-20 04:00PM  
Nov-09-20 05:15PM  
04:54PM  
04:01PM  
02:45PM  
09:00AM  
Nov-06-20 10:18AM  
Nov-04-20 11:10AM  
Nov-02-20 12:31PM  
11:45AM  
Oct-19-20 07:56AM  
Oct-15-20 10:45AM  
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL A Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBERTS EIRYChief Medical OfficerJan 10Sale74.502,632196,08821,279Jan 12 05:53 PM
Gano KyleChief Business Development OffJan 05Option Exercise8.6628,266244,784133,250Jan 07 06:04 PM
Gano KyleChief Business Development OffJan 05Sale85.5028,2662,416,751104,984Jan 07 06:04 PM
ABERNETHY MATTChief Financial OfficerDec 01Sale82.591,645135,85216,349Dec 03 05:02 PM
Grigoriadis Dimitri E.Chief Research OfficerOct 07Option Exercise43.245,000216,20087,273Oct 12 06:32 PM
LYONS GARY ADirectorOct 07Sale105.065,000525,294208,697Oct 12 06:34 PM
Grigoriadis Dimitri E.Chief Research OfficerOct 07Sale104.818,000838,51082,273Oct 12 06:32 PM
Cooke JulieChief Human Resources OfficerOct 04Sale101.73987100,40814,841Oct 06 04:37 PM
BENEVICH ERICChief Commercial OfficerAug 16Sale89.625,628504,39515,608Aug 18 06:18 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJul 27Sale93.8016,7091,567,33615,801Jul 29 05:32 PM
LYONS GARY ADirectorJun 10Sale100.2710,0001,002,743213,697Jun 14 08:25 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Option Exercise35.991,70061,18333,610Feb 12 08:27 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Sale119.961,700203,92632,510Feb 12 08:27 PM
Lippoldt DarinChief Legal OfficerFeb 09Option Exercise35.9936,1941,302,62264,361Feb 09 09:16 PM
Lippoldt DarinChief Legal OfficerFeb 09Sale116.1736,1944,204,83134,361Feb 09 09:16 PM
Lippoldt DarinChief Legal OfficerFeb 08Sale116.723,407397,67431,914Feb 09 09:16 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 08Sale116.7510,4661,221,864446,144Feb 09 09:17 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 08Sale116.692,708315,99983,456Feb 09 09:18 PM
ROBERTS EIRYChief Medical OfficerFeb 08Sale116.782,363275,94417,231Feb 09 09:21 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 08Sale116.813,261380,92930,437Feb 09 09:20 PM
Cooke JulieChief Human Resources OfficerFeb 08Sale116.731,338156,18912,915Feb 09 09:24 PM
BENEVICH ERICChief Commercial OfficerFeb 08Sale116.824,270498,84218,018Feb 09 09:26 PM
ABERNETHY MATTChief Financial OfficerFeb 08Sale116.822,910339,94213,043Feb 09 09:30 PM
Bozigian Haig P.Chief Development OfficerFeb 08Sale116.803,842448,749154,934Feb 09 09:27 PM
Gano KyleChief Business Development OffFeb 08Sale116.853,693431,518102,406Feb 09 09:42 PM
Gano KyleChief Business Development OffFeb 05Sale114.002,677305,18498,663Feb 09 09:42 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale113.7970480,109153,328Feb 09 09:27 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale114.0380992,24716,434Feb 09 09:26 PM
Cooke JulieChief Human Resources OfficerFeb 05Sale113.8660568,88612,125Feb 09 09:24 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale114.1586598,73929,675Feb 09 09:20 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale113.7660568,82382,169Feb 09 09:18 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale114.162,422276,504443,249Feb 09 09:17 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale114.0560569,00330,627Feb 09 09:16 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 26Option Exercise35.991,10039,58929,602Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 26Option Exercise41.7830012,53416,105Jan 27 08:58 PM
BENEVICH ERICChief Commercial OfficerJan 26Sale120.0040048,00015,705Jan 27 08:58 PM
LYONS GARY ADirectorJan 26Sale120.0040048,000223,697Jan 27 09:53 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 26Sale119.971,100131,96529,002Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 25Option Exercise41.783,477145,26920,882Jan 27 08:58 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 25Option Exercise34.4617,570605,47037,960Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 25Sale120.035,077609,37115,805Jan 27 08:58 PM
LYONS GARY ADirectorJan 25Sale120.031,600192,047224,097Jan 27 09:53 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 25Sale119.9717,5702,107,81229,002Jan 27 09:30 PM